Compare SPDR Gold Trust (GLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs BIO-TECHNE Corp — how do they compare? SPDR Gold Trust trades at $400.3, while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while SPDR Gold Trust pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | TECH | |
|---|---|---|
52-Week High | $495.90 | $72.29 |
52-Week Low | $305.27 | $43.31 |
Market Cap | — | $11.24B |
Sector | — | Health |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD trades at $398.47, up 2.26% in the past 24 hours, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $399, with support at $397 and resistance at $400. Recent news highlights gold's rebound potential, citing central bank buying and softer Fed expectations as tailwinds. Financial ratios are unavailable, but the ETF's performance aligns with spot gold trends, which have gained momentum from geopolitical and macroeconomic factors.
The outlook for GLD is positive, with technical strength and supportive sentiment suggesting potential upside toward $402–$404 resistance. Risks include sensitivity to interest rate shifts and dollar strength, while analyst optimism centers on gold's safe-haven appeal. Investors should weigh ETF costs against physical gold alternatives, as momentum may hinge on sustained demand and economic data.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
